Aimmune shares surge 10% on positive late-stage trial results for peanut allergy drug

Aimmune shares surge 10% on positive late-stage trial results for peanut allergy drug  MarketWatch Aimmune's peanut allergy drug meets main goal of key study  Reuters Peanut allergy therapy scores trial win, putting it in line to possibly become first protective treatment  STATFull coverage

Read More ...
Aimmune shares surge 10% on positive late-stage trial results for peanut allergy drug published February 20, 2018 at 09:01PM. Original Source Link : https://www.marketwatch.com/story/aimmune-shares-surge-10-on-positive-late-stage-trial-results-for-peanut-allergy-drug-2018-02-20

loading...